Chowdappa Ramachandra, Tiwari Ajeet Ramamani, Ranganath Namrata, Kumar Rekha V
Department of Surgical Oncology, Kidwai Cancer Institute, Bengaluru, India.
Department of Anaesthesia and Pain Relief, Kidwai Cancer Institute, Bengaluru, India.
J Gastrointest Oncol. 2019 Apr;10(2):307-313. doi: 10.21037/jgo.2018.12.03.
Little has been reported regarding differences between malignancies that develop at the anastomotic site (ASC) and those that develop at the remnant stump (RSC) in gastric stump carcinomas (GSC). The purpose of our study was to compare clinical, pathological and survival characteristics of ASC patients with those of RSC patients.
Patients who underwent surgery for GSC between January 2005 and December 2017 were analyzed. Of the total 112 patients, 22 patients were excluded from the study due to extensive loss of data. Ninety patients underwent curative resection and were evaluated based on anatomic site at which they developed malignancy, i.e., ASC and RSC. Clinical, pathological and survival characteristics were assessed.
As per Lauren's classification, diffuse and intestinal variety were significantly associated with ASC (P=0.0001) and RSC (P=0.0001) respectively. RSC was associated with lower pT [pT2, 15/33 (45.5%), P=0.0002]. ASC was significantly associated with higher pN [pN3, 30/57 (52.6%), P=0.0013], stage [stage III, 48/57 (84.2%), P=0.0022], positive mesenteric nodes (P=0.006) and poor 3-year survival (10.5% versus 36.4%, P=0.003).
ASC is substantially different than RSC. ASC is more aggressive disease compared to RSC and has different pathophysiology, higher rates of nodal involvement (both primary and mesenteric), presents with higher stage and has significantly poor 3-year survival.
关于胃残端癌(GSC)吻合口部位发生的恶性肿瘤(ASC)与残端发生的恶性肿瘤(RSC)之间的差异,鲜有报道。我们研究的目的是比较ASC患者与RSC患者的临床、病理和生存特征。
分析2005年1月至2017年12月期间接受GSC手术的患者。在总共112例患者中,22例患者因数据大量缺失被排除在研究之外。90例患者接受了根治性切除,并根据发生恶性肿瘤的解剖部位,即ASC和RSC进行评估。评估临床、病理和生存特征。
根据劳伦分类法,弥漫型和肠型分别与ASC(P = 0.0001)和RSC(P = 0.0001)显著相关。RSC与较低的pT相关[pT2,15/33(45.5%),P = 0.0002]。ASC与较高的pN显著相关[pN3,30/57(52.6%),P = 0.0013]、分期[III期,48/57(84.2%), P = 0.0022]、阳性肠系膜淋巴结(P = 0.006)以及较差的3年生存率(10.5%对36.4%,P = 0.003)。
ASC与RSC有很大不同。与RSC相比,ASC是侵袭性更强的疾病,具有不同的病理生理学,淋巴结受累率更高(包括原发和肠系膜淋巴结),分期更高,3年生存率显著较差。